Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
US9283276B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 14, 2008 |
| Grant date | Mar 15, 2016 |
| Priority date | — |
| Expiry date | Oct 18, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.